12:00 AM
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

PX-866: Phase I/II started

Oncothyreon began an open-label, dose-escalation, U.S. Phase I/II trial to evaluate once-daily oral PX-866 plus Erbitux cetuximab in a 21-day cycle. The Phase I portion will determine the maximum tolerated dose (MTD) or recommended dose of PX-866 in up to 18 patients...

Read the full 197 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >